Stocker Nicolas, Gaugler Béatrice, Labopin Myriam, Farge Agathe, Ye Yishan, Ricard Laure, Brissot Eolia, Duléry Remy, Sestili Simona, Battipaglia Giorgia, Médiavilla Clémence, Paviglianiti Annalisa, Banet Anne, Van De Wyngaert Zoe, Ledraa Tounes, Mohty Mohamad, Malard Florent
INSERM, Centre de Recherche Saint-Antoine (CRSA) Sorbonne Université Paris France.
Service d'Hématologie Clinique et Thérapie Cellulaire Hôpital Saint-Antoine, AP-HP Paris France.
Clin Transl Immunology. 2020 Sep 23;9(9):e1171. doi: 10.1002/cti2.1171. eCollection 2020.
Haploidentical haematopoietic cell transplantation (Haplo-HCT) using peripheral blood stem cell (PBSC) grafts and post-transplant cyclophosphamide (PTCy) is being increasingly used; however, data on immunological reconstitution (IR) are still scarce.
This retrospective study evaluated T-cell immunological reconstitution in 106 adult patients who underwent allogeneic haematopoietic cell transplantation for haematologic malignancies between 2013 and 2016.
At D30, while conventional T cells reached similar median counts in Haplo-HCT recipients ( = 19) and controls ( = 87), γδ and Vδ2 T-cell median counts were significantly lower in Haplo-HCT recipients and it persists at least until D360 for Vδ2 T cells. PTCy induces a significant reduction in early γδ and Vδ2 T-cell proliferation at D 7. At one year, the rate of increase in Epstein-Barr virus (EBV) viral load was significantly higher in Haplo-HCT recipients as compared to controls (61% versus 34%, = 0.02). In multivariate analysis, a higher γδ T-cell count (> 4.63 μL) at D30 was the only independent parameter significantly associated with a reduced risk of increase in EBV viral load (RR 0.34; 95% CI, 0.15-0.76, = 0.009).
Immunological reconstitution of γδ T cells is significantly delayed after Haplo-HCT using PTCy and low-dose ATG and is associated with an increased risk of increase in EBV viral load.
使用外周血干细胞(PBSC)移植物和移植后环磷酰胺(PTCy)的单倍体相合造血细胞移植(Haplo-HCT)的应用越来越广泛;然而,关于免疫重建(IR)的数据仍然很少。
这项回顾性研究评估了2013年至2016年间106例接受异基因造血细胞移植治疗血液系统恶性肿瘤的成年患者的T细胞免疫重建情况。
在第30天,虽然单倍体相合造血细胞移植受者(n = 19)和对照组(n = 87)的常规T细胞达到相似的中位数计数,但单倍体相合造血细胞移植受者的γδ和Vδ2 T细胞中位数计数显著更低,并且Vδ2 T细胞至少持续到第360天。PTCy在第7天可显著降低早期γδ和Vδ2 T细胞增殖。在1年时,单倍体相合造血细胞移植受者的EB病毒(EBV)病毒载量增加率显著高于对照组(61%对34%,P = 0.02)。在多变量分析中,第30天较高的γδ T细胞计数(>4.63 μL)是与EBV病毒载量增加风险降低显著相关的唯一独立参数(风险比0.34;95%置信区间,0.15 - 0.76,P = 0.009)。
使用PTCy和低剂量抗胸腺细胞球蛋白进行单倍体相合造血细胞移植后,γδ T细胞的免疫重建显著延迟,并且与EBV病毒载量增加风险增加相关。